Department of Radiopharmaceuticals, National Medicines Institute, 00-725 Warsaw, Poland.
Nucl Med Biol. 2010 Oct;37(7):795-803. doi: 10.1016/j.nucmedbio.2010.04.013.
Interleukin-2 (IL-2) when radiolabelled with (99m)Tc has been proved useful in imaging the side of lymphocytic infiltration in patients with autoimmune disorders and plays a significant role as a T-cell imaging agent. However, the labelling procedures used so far appeared to be rather complex and laborious. The aim of present study was to develop an efficient procedure of (99m)Tc-labelling of recombinant human interleukin-2 (rhIL-2) via hydrazinonicotinamide (HYNIC) to develop a dry kit formulation.
Various molar ratios of rhIL-2/HYNIC (from 1:2 to 1:12) were used at the conjugation step. The conjugates were purified on a PD-10 column to remove the excess of unbound HYNIC, as well as of any aggregates. The final peptide concentration was quantified by the BCA method, and the number of HYNIC molecules incorporated into a rhIL-2 molecule was determined based on the reaction with 2-sulfobenzaldehyde. The (99m)Tc-labelling was optimized using various amounts of HYNIC-rhIL-2, (99m)Tc, SnCl(2), tricine and nicotinic acid (NA). Quality control included GF-HPLC, ITLC, SDS-PAGE and biological assay. Biodistribution studies were performed in Swiss mice and Wistar rats.
Generally, the highest radiolabelling yields were achieved when the HYNIC-rhIL-2 conjugates of ca. 2-4 HYNIC molecule substitution ratios were used. The optimal pH of the reaction medium was found to be in the range of 6.5 to 7.0. GF-HPLC analysis indicated that monomer and aggregates of (99m)Tc-HYNIC-rhIL-2 are formed during radiolabelling. At optimized conditions of wet radiolabelling, the (99m)Tc-HYNIC-rhIL-2 monomer was obtained with radiochemical purity >99%, specific activity of ca. 4 GBq/mg rhIL-2 and overall yield of ca. 65%. The two-vial freeze-dried kit was prepared: the first vial contained 30 μg HYNIC-rhIL-2, co-ligands, buffer and antioxidant; the second vial contained tricine and SnCl(2). The monomer of (99m)Tc-HYNIC-rhIL-2 was obtained by gel chromatography on a PD-10 column. No differences between labelled and unlabelled IL2 in terms of biological activity were observed.
Our study shows that rhIL-2 can be efficiently radiolabelled with (99m)Tc via HYNIC, with tricine and NA as co-ligands using a two-vial freeze-dried kit. This enables the preparation of sterile and ready-to-use (99m)Tc-HYNIC(tricine,NA)-rhIL-2 within 1 h.
白细胞介素 2(IL-2)用(99m)Tc 放射性标记后,已被证明可用于成像自身免疫性疾病患者淋巴细胞浸润侧,并作为 T 细胞成像剂发挥重要作用。然而,迄今为止使用的标记程序似乎相当复杂和费力。本研究的目的是通过肼基烟酰胺(HYNIC)开发一种有效的重组人白细胞介素-2(rhIL-2)(99m)Tc 标记方法,以开发一种干试剂盒配方。
在偶联步骤中使用 rhIL-2/HYNIC 的各种摩尔比(从 1:2 到 1:12)。将缀合物在 PD-10 柱上纯化,以去除未结合的 HYNIC 和任何聚集体。通过 BCA 法定量测定肽的最终浓度,并根据与 2-磺基苯甲醛的反应确定掺入 rhIL-2 分子中的 HYNIC 分子的数量。使用各种量的 HYNIC-rhIL-2、(99m)Tc、SnCl2、三羟甲基氨基甲烷(tricine)和烟酸(NA)优化(99m)Tc 标记。质量控制包括 GF-HPLC、ITLC、SDS-PAGE 和生物学测定。在瑞士小鼠和 Wistar 大鼠中进行了生物分布研究。
通常,当使用约 2-4 HYNIC 分子取代比的 HYNIC-rhIL-2 缀合物时,可获得最高的放射性标记产率。发现反应介质的最佳 pH 值在 6.5 到 7.0 之间。GF-HPLC 分析表明,在放射性标记过程中形成了(99m)Tc-HYNIC-rhIL-2 的单体和聚集体。在湿放射性标记的优化条件下,获得了放射性化学纯度>99%、比活度约 4GBq/mg rhIL-2 和总体产率约 65%的(99m)Tc-HYNIC-rhIL-2 单体。制备了两管冻干试剂盒:第一管含有 30μg HYNIC-rhIL-2、共配体、缓冲液和抗氧化剂;第二管含有三羟甲基氨基甲烷和 SnCl2。通过 PD-10 柱上的凝胶色谱法获得(99m)Tc-HYNIC-rhIL-2 的单体。标记和未标记 IL2 的生物学活性没有差异。
我们的研究表明,rhIL-2 可以通过 HYNIC 与(99m)Tc 有效标记,使用三羟甲基氨基甲烷和 NA 作为共配体,使用两管冻干试剂盒。这使得在 1 小时内可以制备无菌且可立即使用的(99m)Tc-HYNIC(三羟甲基氨基甲烷,NA)-rhIL-2。